OrthogenRx, Inc.
- Home
- Companies
- OrthogenRx, Inc.
- Products
- OrthogenRx - Model GenVisc 850 - ...
OrthogenRx - Model GenVisc 850 -5-Injection Hyaluronic Acid Regimen
FromOrthogenRx, Inc.
Knee pain caused by osteoarthritis is suffered by millions of people worldwide1. GenVisc 850, a 5-injection hyaluronic acid from OrthogenRx, may help relieve OA-related knee pain in patients who are unresponsive to non-pharmacologic therapy and simple analgesics. GenVisc 850 is approved for 5 injections, but some patients may benefit from as few as 3 injections.
Most popular related searches
Proven
- GenVisc 850 is approved in 64 countries with over 45 million syringes distributed worldwide
- GenVisc 850 has the largest and longest duration double blind clinical study of hyaluronic acids for knee osteoarthritis.
- GenVisc 850 has been published in over 30 clinical studies.
Safe
- Safe as saline placebo
- Free of avian proteins
- Demonstrated safe for repeat injection cycles
Effective
- Provides significant pain relief with results that last
- Demonstrated improvement in pain relief up to 30 weeks post first injection cycle
- Demonstrated improvement of total WOMAC index at 30 weeks: Pain, stiffness and functional capacity